Compare Novavax Inc (NVAX) vs Vital Farms Inc (VITL) Price & Performance

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

VITL trades at $11.35, down 0.8% daily, with a bearish technical signal driven by moving averages. Recent Q2 2026 results showed a loss of $0.47 per share, beating expectations but reflecting revenue declines amid industry oversupply challenges. The company secured a $125 million term loan in August 2026 to bolster liquidity, as net cash flow remained negative. Valuation ratios like P/E of 11.77 and P/S of 0.67 suggest potential undervaluation, but profitability metrics are weak with net income margin at 0.02%.

The outlook is mixed: analyst consensus is bullish with a $13.00 price target, but execution risks from cost pressures and competitive gaps persist. Near-term catalysts include Q3 2026 earnings, while downside risks involve ongoing operational challenges and class-action litigation noted in May 2026. The stock's proximity to its 52-week low underscores cautious sentiment despite institutional support.